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Abstract
Historically, phase II oncology trials assessed a treatment’s efficacy by examining its tumor response rate in a single-arm
trial. Then, approximately 25 years ago, certain statistical and pharmacological considerations ignited a debate around
whether randomized designs should be used instead. Here, based on an extensive literature review, we review the arguments
on either side of this debate. In particular, we describe the numerous factors that relate to the reliance of single-arm trials on
historical control data and detail the trial scenarios in which there was general agreement on preferential utilization of
single-arm or randomized design frameworks, such as the use of single-arm designs when investigating treatments for rare
cancers. We then summarize the latest figures on phase II oncology trial design, contrasting current design choices against
historical recommendations on best practice. Ultimately, we find several ways in which the design of recently completed
phase II trials does not appear to align with said recommendations. For example, despite advice to the contrary, only 66.2% of
the assessed trials that employed progression-free survival as a primary or coprimary outcome used a randomized compara-
tive design. In addition, we identify that just 28.2% of the considered randomized comparative trials came to a positive con-
clusion as opposed to 72.7% of the single-arm trials. We conclude by describing a selection of important issues influencing
contemporary design, framing this discourse in light of current trends in phase II, such as the increased use of biomarkers
and recent interest in novel adaptive designs.
The classical paradigm of oncological drug development com-
prises three phases of clinical trials. In phase I, a treatment’s
toxic effects are assessed and the recommended dose(s) for sub-
sequent trials determined. Phase II provides the first assess-
ment of a regimen’s efficacy, with success typically resulting in
a confirmatory phase III trial being conducted. Phase II trials
thus play a pivotal role, providing the principal evidence for
deciding whether to carry out a large phase III trial. The conse-
quences of an incorrect decision at this time can be far-
reaching: halting the development of an effective regimen could
deprive future patients of a valuable treatment option, whereas
continuing to develop a futile regimen could waste substantial
resources. Accordingly, the optimal approach to conducting
phase II trials has received much attention.
Historically, given the scarcity of effective anticancer agents
in the 1950s, the accepted perspective was that phase II should
act as a screening process to efficiently weed out inactive regi-
mens (1,2). For this, a short-term surrogate endpoint for
long-term clinical benefit was required. A binary tumor re-
sponse indicator, later formally defined via RECIST (3), became
the endpoint of choice (2). Furthermore, Gehan offered in 1961 a
design that would long remain the primary approach to phase II
oncology trial design (1). Based on the belief of the day that a re-
sponse rate of less than 20% was not promising, he recom-
mended that 14 patients be recruited and observed for tumor
response. If no response was observed, this would ascertain
with 95% confidence that the true response rate was less than
20%. With at least one response observed, a second stage of re-
cruitment and observation would be conducted to accurately
estimate the true response rate.
Unfortunately, Gehan’s design provided no guidance on
whether the observed response rate was clinically meaningful.
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Consequently, as the number of available effective oncology
drugs increased during the 1970s, phase II trials shifted to de-
mand a higher standard of evidence of potential clinical benefit
(2). The prevailing techniques for achieving this were Simon’s
two-stage single-arm designs (4), which were constructed to al-
low a formal hypothesis test to be conducted on the tumor re-
sponse rate. Simon’s designs, like Gehan’s, experienced a
sustained period as the preferred approach in phase II. Thus,
unlike in many disease settings, phase II cancer trials were tra-
ditionally nonrandomized. Moreover, they almost all used tu-
mor response as their primary outcome (5). By the mid-1990s,
however, questions over the optimality of this convention be-
gan to arise.
In this article, we focus on these questions, in particular ex-
amining opinions on the role of randomization in phase II. To
provide a comprehensive overview of this subject, we base our
discourse on a completed narrative literature review (see
Supplementary Methods and Supplementary Tables 1–5 for
details on this review). We proceed by describing one of the pri-
mary reasons for the now evident changes in phase II design.
We then discuss the arguments put forth for and against the
use of randomization, along with the real-world evidence and
statistical investigations that complicate this debate. Our dis-
course then turns to consider the current design of phase II on-
cology trials and how such design aligns with past opinions on
best practice. We conclude by highlighting current issues that
are likely to influence changes in the design of future phase II
trials.
Changing Phase II Design
Arguably the principal driver of change in phase II oncology trial
design was the advent of molecularly targeted agents (MTAs).
Classic anticancer agents were cytotoxic; thus it was considered
reasonable to assess their efficacy via their ability to shrink
tumors, and the fact that tumors do not typically spontaneously
shrink meant many accepted the lack of a randomized compar-
ator arm. However, it was anticipated that the new MTAs may
often be cytostatic, delaying tumor progression rather than
leading to tumor shrinkage (6,7). Accordingly, it was feared that
the use of tumor response as a primary endpoint may lead to
many novel regimens that do increase clinical benefit being
rejected from further consideration (8–11). Thus, it was con-
tended that a new approach was required in phase II for cyto-
static agents.
Initially, the proposed approaches varied greatly, with some
authors even suggesting that phase II be skipped (12).
Unsurprisingly, such suggestions were not widely favored. It
was acknowledged that although this may seem a desirable
means of reducing development plan sample sizes, the ever-
rising cost of phase III studies, and the scarcity of available
patients to enroll in trials, would make it impossible to test all
regimens in this manner (9,13,14). Further, given a preliminary
efficacy assessment could be acquired in phase II using a rela-
tively small number of patients, it would be unethical to expose
large numbers of patients to a regimen for which little evidence
of efficacy exists (9).
More reasonably, calls for the use of an alternative primary
endpoint in phase II trials of cytostatic agents soon grew (13,15).
In particular, progression-free survival (PFS) was much advo-
cated because an assessment of time until disease progression
would more accurately capture the benefits of cytostatic agents.
Furthermore, PFS, it was argued, would be more efficient to
estimate than overall survival and would not be affected by sal-
vage treatment. However, PFS is highly dependent on a dis-
ease’s natural history. It was thus contended that with this
necessary change in endpoint, so came a necessary change in
design to use randomization (11,16–19). With this, one of the
primary reasons randomization has been advocated for in
phase II was apparent.
Arguments for and Against the Use of
Randomization in Phase II
Along with changes proposed to phase II design because of the
rise of MTAs, appeals for the use of randomization no matter
the regimen under investigation or the chosen primary end-
point also increased. Here, we discuss the arguments for and
against randomization that have appeared in the literature, pro-
viding an overview in Table 1. Note that we concentrate our dis-
cussion on randomization as a means of formally comparing
treatments using a hypothesis test because the majority of
articles have focused on the use of randomization for this
purpose. Thus, for brevity, when we now refer to randomized
designs, we mean randomized comparative designs. However,
many of the following points are also relevant to a debate on
the utility of randomized noncomparative designs.
At the center of most discussions on phase II design has
been the key assumption of a single-arm trial: The historical
controls used to design the current study provide a fair repre-
sentation of the probable outcome for patients in the new trial
if they were given the same control treatment. Many have noted
that, because of improvements in the standard of care, earlier
detection rates, institutional variabilities, and differences in
prognostic factors, only in rare scenarios would historical con-
trols provide such a representation (20–23).
Potential differences in prognostic factors between historical
controls and concurrent participants were seen as particularly
problematic because it was well recognized that unknown prog-
nostic factors can profoundly affect a single-arm trial’s error
rates (23,24). A modeling-based approach was suggested as a
possible solution to accounting for such prognostic variables
(25). However, although proponents of randomization acknowl-
edged that this could improve on simple unadjusted compari-
sons to historical controls, given the majority of interindividual
variability remains unexplained after accounting for all mea-
sured predictors (8,16,26,27), they argued that such adjustment
procedures were not widely applicable or reliable (20,26). So too
did others note that the desire for a new agent to “look good”
could manifest itself in setting the historical response rate too
low (28,29) or the enrollment only of patients who “look
promising” (30). Each of these problems, it was maintained,
would not be an issue in a randomized trial (17,18,20,22–
24,26,30–33).
Nonetheless, numerous publications still argued in favor of
single-arm designs (23,34–37), claiming that they can be readily
used given high enough confidence in the historical data (23,
34). A melanoma overall survival database was in particular a
heralded means through which successful single-arm studies
had been conducted (25). In addition, those in favor of single-
arm designs noted flaws in the supposed advantages of ran-
domization, arguing that the purported ability of randomized
phase II trials to balance prognostic factors was an illusion,
because the majority of such trials used simple randomization,
which would be unlikely to provide balance for typical phase II
sample sizes (23,36,38–40). Moreover, as was feared about
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single-arm trials, randomized phase II trials could also feature
highly selected patients (17) and easily fall foul of differential
loss to follow-up or patient drop-out (41). As a counterpoint, it
was argued that randomization was a better way to handle
many sources of bias and actually the only way to make detec-
tion and quantification of imbalances possible (23).
Randomized phase II trials have also been viewed as trou-
bling because of the possibility that investigators will mistak-
enly treat their results as though they are from a phase III trial
(42), a claim arguably supported by the large number of compar-
isons performed at the end of noncomparative trials (38). This
though, others claimed, should not be an argument against ran-
domization, and in fact a highly statistically significant P value
from a randomized phase II trial could provide enough evidence
for a licensing claim, which is not in general possible from a
single-arm study (23).
Perhaps the most common argument against randomizing
was its associated cost and complexity, with many fearful of the
resultant requisite sample size, the fact that randomized trials
can be more complex for patients to understand, and that it
may be difficult to find patients willing to be randomly assigned
(23,34,35). This viewpoint was supported by a review that found
27% of conducted randomized phase II studies had encountered
“sizeable problems” (23). Those in favor of randomization, how-
ever, argued that in general randomization would provide more
reliable data (8), and because “you get what you pay for,” (33)
the increased cost should be accepted (13). Furthermore, this ar-
gument ignored the fact that randomizing in phase II could de-
crease the cost of a project overall (20,26,43) and that whereas it
may seem appealing to use single-arm trials to develop drugs
quickly, or to allow expedient publication, in the long term we
all had more to gain from well-designed, randomized phase II
trials (33).
Advocates of randomization further attacked the issue of
larger requisite sample sizes by arguing for one-sided hypoth-
esis tests and allowance for increased type-I error rates
(9,14,16,17,20,29). Given the purpose of phase II is to screen
and select, this was claimed to be entirely appropriate (16) and
also logical for ethical reasons (17). As a counterpoint, it was
noted that the advantages of increasing error rates to reduce
sample sizes in phase II are negated by the cost associated
with conducting more phase III trials with inactive agents.
However, pro-randomization researchers contended that
some control is better than none and highlighted that the
type-I error rate in single-arm trials is actually unknown
(23,26).
Arguments in favor of single-arm designs were also made on
ethical grounds, with some desiring to provide all enrolled
patients the experimental regimen (34). Others, though, stated
that randomizing may be more ethical because the
Table 1. A summary of the key arguments or counterpoints that have historically been put forward for and against the use of randomization in
phase II oncology trials
Consideration For randomization Against randomization
Molecularly targeted agents may often be cy-
tostatic and not in general lead to tumor
shrinkage.
PFS* should be the preferred primary out-
come for cytostatic agents, which in turn
makes randomization preferable.
The use of tumor response is still appropriate
because several cytostatic agents have led
to statistically significant tumor regression.
Success in phase II should reliably predict
that clinical benefit will be observed in
phase III.
The classical single-arm paradigm has per-
formed poorly in predicting clinical benefit
in phase III; randomized designs would
perform better.
No evidence is available to suggest the use of
randomization in phase II has improved
success in phase III.
Randomized phase II designs appear more
similar to phase III designs than conven-
tional phase II designs.
A highly statistically significant P value from
a randomized trial would provide a strong
case for seeking regulatory approval.
Investigators may incorrectly interpret the
results of randomized phase II trials as
though they are from a large phase III
study.
Single-arm trials use historical control data
to specify their design.
Reliance on historical control data for setting
target response makes results of single-
arm trials unreliable.
For several diseases, well-established resour-
ces allow for determination of historical re-
sponse to treatment.
Prognostic factors can differ substantially be-
tween patients, and these are often strong
predictors of response to treatment.
Randomization should balance prognostic
factors between arms, allowing for more
reliable assessment of efficacy. Attempts to
account for such covariates in single-arm
data using modeling are unreliable.
Randomization cannot guarantee prognostic
factors will be balanced, especially in
smaller trials, and modeling can be used to
account for such variables in single-arm
studies.
There is a trade-off between trial complexity
and quality.
In conducting a randomized trial, you “get
what you pay for,” with better quality data
accrued.
Single-arm trials are simpler and easier to
conduct.
Clinical trials should be conducted with as
few participants as required to control
type-I/II error rates to specified levels.
One-sided testing with increased type-I/II er-
ror rates allows randomized trials to be
conducted with achievable sample sizes.
Only in a randomized trial are these error
rates ever known.
Single-arm trials require a much smaller
sample size, and modifying error rates to
reduce that required by a randomized trial
would only increase failure in phase III.
Single-arm designs should be preferred from
an ethical standpoint.
In general, there is equipoise, making ran-
domized trials entirely appropriate.
Randomized trials are not ethical when large
responses have been observed previously
because not all participants have access to
a potentially better treatment.
*PFS ¼ progression-free survival.
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experimental treatment could be inferior (26), contending that
in most cases there is equipoise (33).
Several authors were critical of the approach randomization
implies about our method of identifying new treatments. Most
prominently, Stewart and Kurzrock argued that using random-
ized designs in phase II to balance for characteristics that might
confound efficacy assessment is the antithesis of personalized
medicine and that unless the target required for drug activity is
very common or we know for each patient whether his or her
tumor expressed the required target, randomization could pro-
duce misleading results (44). This argument, though, was not
logical to all, with it noted that any experienced group of inves-
tigators would identify a subgroup of patients with exceptional
outcomes within a randomized trial (33).
Finally, it is important to note that deliberations on what
should become the typical primary endpoint in a phase II trial
have long interweaved the debate around randomization, a con-
sequence of a desire for improved endpoints on which to select
treatments (10,45–50). Here, though, we have limited our discus-
sions to our primary interest: the suitability of single-arm
designs in phase II. For an in-depth history of endpoints that
could be utilized in oncology trials, we refer the reader to
Wilson et al. (51).
Practical Evidence on the Outcome of Utilizing
Randomized or Nonrandomized Designs
Along with the discussions outlined above, several authors
have provided evidence on the result of using different design
frameworks in phase II in practice. In particular, much evidence
has suggested that the classical approach has contributed to the
failure of phase II trials to predict long-term survival benefits.
Kola and Landis (52) highlighted that 60% of regimens that had
“promising” activity in single-arm phase II trials failed to dem-
onstrate superiority in phase III. Zia et al. (53) identified that re-
sponse rates were regularly lower in phase III trials than in their
preceding phase II studies. Maitland et al. (54) analyzed all
phase II combination therapy trials published in 2001–2002 and
found that despite 72% being deemed successful, the likelihood
that an ensuing trial would demonstrate important effects
within 5 years was only 3.8%. Ratain (55) pointed to the ex-
tremely low positive predictive value of classical II trials.
Finally, Vickers et al. (29) identified that 46% of surveyed
phase II studies that required historical data did not cite the
source of these data. Even more troubling was their finding that
those trials that failed to cite prior data suitably were more
likely to declare an agent to be active. For many, this was evi-
dence that a higher bar now needed to be set for progressing to
phase III. The solution to attaining this higher bar, it was ar-
gued, was randomization in phase II (13,17,20,30,33,56).
Complicating the picture, though, were the many results
that favored the use of single-arm designs and tumor response.
Goffin et al. (57) identified that higher overall response rates in
phase I and II were predictive of regulatory approval in a range
of cancer types. Moreover, El-Maraghi and Eisenhauer (50)
established, in 89 surveyed phase II trials, higher response rates
were predictive of regulatory approval for MTAs. Tsimberidou et
al. (58) noted that of 31 drugs approved in 1973–2006 without a
randomized trial, 30 remained fully approved. Finally, Chan et
al. (59), in examining all phase III trials of targeted therapies
against advanced cancers from 1985–2005 and their preceding
phase II studies, found that randomization in phase II was not
more likely to lead to a positive phase III result.
Consequently, it was argued that success issues in phase III
were not due to the use of single-arm trials in phase II but to
how these trials were planned and interpreted, and thus we
should focus on conducting high-quality single-arm trials (23).
Not all were convinced by these presentations, however (20,60),
with Gan et al. (23) in particular noting that such reviews are bi-
ased because many trials are never published, and it is likely
that a higher proportion of randomized phase II trials would be
published because of their greater intrinsic value.
Statistical Investigations of Randomized and
Nonrandomized Design Operating
Characteristics
Thus, arguments for and against classical phase II designs could
readily be made based on the available evidence from design
use in practice. Hoping to clarify purely statistical recommenda-
tions, several publications have provided quantitative figures
on optimal phase II design.
Firstly, Mariani and Marubini noted that the error rates of
single-arm but not randomized trials are highly sensitive to
the historical control rate assumptions (61). Baey and Le Deley
conducted a similar analysis and argued in favor of random-
ized designs (62). Providing a less favorable view of randomi-
zation, Sharma et al. (63) resampled data from a positive and a
negative phase III trial. They considered a variety of endpoints
and designs, finding that randomized designs performed bet-
ter for PFS at predicting a positive result for the positive trial
but that they had a higher false-negative rate for the negative
trial.
Taylor et al. (64) compared single-arm and randomized
designs using a simulation study. They found that a random-
ized design of equal size to a single-arm trial made the correct
decision more often and that increasing the sample size was
more beneficial to randomized than to single-arm trials. They
concluded that in the presence of uncertainty around the his-
torical response rate, and when a larger sample size is possible,
a randomized design should be used. Similarly, Tang et al. (65)
simulated single-arm and randomized phase II trials using data
from a colorectal cancer study. They found that the false posi-
tive rate of single-arm trials was two to four times higher under
modest drift of several considered patient-selection factors but
that randomized phase II trials came at a cost of two to four
times the sample size. They also argued that given enough
patients, a randomized design was preferable. Sambucini later
came to similar conclusions, having taken a Bayesian approach
to design comparison (66). However, Pond and Abbasi (67), using
a simulation study that modeled numerous potential sources of
variability, argued that single-arm and randomized designs
were both warranted in certain circumstances.
Consensus Opinions on Phase II Design
Thus, in spite of much debate, no consensus on the optimal de-
sign of phase II trials emerged. Nonetheless, several areas of
general agreement are apparent, being for the most part de-
scribed in two articles released following committee discus-
sions (68,69) and in a table provided by Gan et al. (23). In
particular, it was widely accepted that single-arm as well as
randomized designs have a part to play in phase II (23,37,69–71),
with it typically agreed that the number of randomized phase II
trials should increase and PFS should become the conventional
endpoint of choice (37).
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Most authors believed that single-arm trials were acceptable
for single, especially novel, agents when tumor response was
expected (17,19,23,69). They would also be useful for rare cancer
types, for which it may be challenging to enroll enough patients
to conduct a randomized trial (23,34,72), in late disease and sal-
vage settings, and when no standard treatment exists (68,69).
Additionally, if data suggested a response rate that was dramat-
ically higher than that for available therapies, we may forego
randomization (72). They could also be logical in the admittedly
rare situations in which a robust historical database exists (68).
In contrast, randomized designs would be required for com-
bination therapies, because it would otherwise be difficult to
distinguish the contribution of the experimental agent from the
established component (14,68,73). They would be needed for
time-to-event endpoints (3,17,23,69), when there is a lack of
available suitable historical data (9,68,72), or when the target
population is unclear or heterogeneous (69,74,75). However,
investigators were cautioned against conducting small random-
ized trials, with it propositioned that in general we may need to
accept an increase in the size of phase II trials (68).
Finally, many papers agreed that alternative endpoints, out-
side of tumor response, should be given greater consideration
and ultimately be deployed in randomized trials (68,70).
Nonetheless, it was also well recognized that although they
were promising, many alternative endpoints required addi-
tional evaluation and validation before they could be used as
primary outcomes in phase II (76), and thus the choice in prac-
tice would often remain between tumor response and PFS.
Figures on the Contemporary Design of
Phase II Oncology Trials
The number of available phase II designs is now extensive, with
an overview of many provided by Brown et al. (77). Consequently,
several articles have sought to examine how frequently particular
designs have been used. Together, they provide evidence that
arguments for the increased use of randomization have perme-
ated through to practice. Mariani and Marubini found that of
308 phase II trials published in 1997, only four (1.3%) were con-
trolled (5), and Stone et al. examined publications in the Journal of
Clinical Oncology between 1999 and June 2003 and identified only
23 randomized phase II trials out of approximately 250 studies
(16). However, Rubinstein et al. noted in 2011 that 69 (28%) of the
then active National Cancer Institute–sponsored phase II trials
were randomized (19). In addition, Thezenas et al. (78), Ivanova et
al. (79), and Langrand-Escure et al. (80) have all since conducted
reviews of phase II trials, each identifying a large proportion that
incorporated randomization.
Here, we focus on reanalyzing the data from Langrand-
Escure et al. (80), who examined 557 trials published in three top
oncology journals from 2010 to 2015. In Table 2 we present an
assessment of several design characteristics by design type:
Table 2. A summary of the characteristics of phase II oncology trials by type of design used, based on a reanalysis of the data from Langrand-
Escure et al. (80)*
Characteristic
Single-arm,
% (IQR)
Multi-arm nonrandomized,
% (IQR)
Randomized
noncomparative, % (IQR)
Randomized
comparative, % (IQR) P†
Type of therapy
Cytotoxic 84 (26.7) 13 (26.5) 24 (31.6) 27 (23.1) .02
Combination therapy 102 (32.4) 11 (22.4) 27 (35.5) 53 (45.3)
Targeted therapy 62 (19.7) 17 (34.7) 8 (10.5) 16 (13.7)
Other 67 (21.3) 8 (16.3) 17 (22.4) 21 (17.9)
(Co-)Primary endpoint‡
Tumor response 129 (41.0) 18 (36.7) 26 (34.2) 18 (15.4) —
Dichotomized PFS 23 (7.3) 6 (12.2) 9 (11.8) 5 (4.3)
PFS 18 (5.7) 1 (2.0) 5 (6.6) 47 (40.2)
Other 159 (50.5) 26 (53.1) 38 (50.0) 54 (46.2)
Positive result 152 (72.7) 25 (83.3) 39 (70.9) 29 (28.2) <.001
Median type-I error rate (IQR) 5 (5–10) 5 (5–10) 7.1 (5–10) 5 (5–10) .04
Median type-II error rate (IQR) 14 (10–20) 10 (9.8–12.5) 10 (10–20) 20 (15–20) <.001
Median patients analyzed (IQR) 43 (34–58) 72.5 (49.8–111) 92 (72.8–135) 131 (89–182) <.001
*Note that the dataset from Langrand-Escure et al. (80) comprises 557 trial reports. IQR ¼ interquartile range; PFS ¼ progression-free survival.
†In addition, P values for either a chi-squared test of row-column independence or a Kruskal-Wallis test of stochastic dominance, as appropriate, are reported for each
of the characteristics. All statistical tests were two-sided.
‡The percentages for the (co-)primary characteristic section do not add up to 100% because the categories are not mutually exclusive given the allowance for co-pri-
mary endpoints, and consequently a P value is omitted for this section.
Table 3. A summary of the choices of primary/coprimary endpoints in phase II by the type of treatment under investigation, based on a reanal-
ysis of the data from Langrand-Escure et al. (80)*
(Co-)Primary endpoint Cytotoxic No. (%) Combination therapy No. (%) Targeted therapy No. (%)
Tumor response 69 (46.6) 53 (27.5) 35 (34.0)
Dichotomized PFS 5 (3.4) 18 (9.3) 16 (15.5)
PFS 10 (6.8) 38 (19.7) 16 (15.5)
Other 67 (45.3) 92 (47.7) 44 (42.7)
*The percentages do not add up to 100% because the categories are not mutually exclusive given the allowance for co-primary endpoints. PFS ¼ progression-free
survival.
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single-arm, multi-arm nonrandomized, randomized noncom-
parative, and randomized comparative studies, which form the
main types of design in this dataset. In Table 3 we summarize
the choice of primary and coprimary endpoints by the type of
treatment under investigation. Our analyses reveal several im-
portant figures in relation to the aforementioned opinions on
best practice. We provide a summary of these in Box 1.
Firstly, against prevailing opinion, a smaller proportion of
targeted therapies were tested using randomized comparative
designs (13.7%) than cytotoxic therapies (23.1%), and 102 (32.4%)
of the single-arm trials were of combination therapies (Table 2).
Recommendations on the utilization of randomization with PFS
appear to have been better heeded, with 47 (66.2%) of the trials
employing PFS as a primary or coprimary outcome being ran-
domized comparative. However, 18 (5.7%) single-arm trials had
PFS as a primary or coprimary outcome.
The randomized comparative trials on average analyzed ap-
proximately three times as many patients (median ¼ 131, inter-
quartile range [IQR] ¼ 89, 182) as single-arm trials (median ¼ 43,
IQR ¼ 34, 58), exemplifying an ability in many circumstances to
overcome concerns around increased requisite sample sizes
(Table 2). Additionally, though there is evidence that different
type-I error rates have been used across the four design types
(Kruskal-Wallis test, P¼ .04; see Table 2 and Supplementary
Figures 1–2), the lower-quartile, median, and upper-quartile val-
ues used in the single-arm and randomized comparative trials
are equal, suggesting that calls for randomized comparative tri-
als to use increased error rates may not have been realized in
the way many authors desired.
Importantly, Table 2 highlights that among the trials that
reported a conclusion, the analyzed randomized comparative
trials less frequently come to positive conclusions (29 of 103 tri-
als, 28.2%) than single-arm (152 of 209, 72.7%), multi-arm non-
randomized (25 of 30, 82.3%), and randomized noncomparative
trials (39 of 55, 70.9%). This, in particular, raises concerns over
the choice of historical controls and specification of the hypoth-
eses in the single-arm trials.
Finally, in Table 3 we observe that more than 50% of cytotoxic,
combination, and targeted therapy trials have used tumor re-
sponse, PFS, or a dichotomized version of PFS as a primary or
coprimary outcome, with tumor response the most commonly
used endpoint for all three treatment types. Also, perhaps sur-
prisingly given previous recommendations, tumor response was
used more than twice as often as PFS for targeted therapies.
Contemporary Factors Influencing Phase II
Design
Although the use of randomized designs in phase II has in-
creased, an open question exists as to what this has taught us
about randomization’s applicability, particularly given it does
not appear to have improved success rates in phase III (81).
Furthermore, although there has been much interest in the use
of novel endpoints, this has not materialized in the way many
hoped it would (82). We may therefore still question whether
poor performance in phase III is due to the methods typically
used in phase II. Careful design choice in phase II thus remains
paramount. In addition, several contemporary articles highlight
additional important considerations for future phase II trials.
Firstly, despite historical agreement on the suitability of
single-arm designs for rare cancers, whether this should be uni-
versally accepted has recently been challenged (83,84). It has
been argued that the field of oncology performs a disservice to
patients with rare tumors when we accept medications using
inferior levels of evidence. It has also been maintained that
although randomized trials are difficult to conduct in rare
tumors, large randomized trials have been conducted for even
ultra-rare tumors, providing reliable results to important ques-
tions (83). Thus, randomization has more to do with our expect-
ations than tumor incidence. Accordingly, we should not accept
that randomization is not required for rare conditions. Whether
randomization can, and will, be more commonly used in rare
cancer types remains to be seen.
Moreover, in recent years, there has been increased interest in
the use of novel adaptive designs in phase II, such as umbrella
and basket designs (85). How this complicates the debate on
the use of randomization, and the preferred primary
endpoint, remains unclear. Many of the available adaptive
designs applicable in phase II are nonrandomized in nature, yet
one may expect that adaptation might improve trial efficiency in
a way that randomization becomes more feasible. Furthermore,
adaptive designs typically require a primary outcome that can be
evaluated quickly. This implies that PFS, which has been much
argued for historically, may be difficult to use with such designs.
Perhaps most important are considerations around the de-
sign of trials that use biomarkers given their evident increased
use (80). It has long been argued that randomization would be
needed for biomarker-guided trials, not only because historical
data would be unavailable but also because of the requirement
to validate the biomarker as a predictive marker of efficacy
(33,86–88). However, it has been pointed out that conducting
randomized trials in prespecified subgroups with very low-
frequency biomarkers may be difficult (89) and that randomized
assignment may be unnecessary if tumor shrinkage is the pri-
mary endpoint, because only predictive factors would be
expected to correlate with shrinkage (37).
Box 1. A summary of the key findings, in light of historical
recommendations, from the reanalysis of the data from
Langrand-Escure et al. (80)
Finding
102 (32.4%) of the single-arm trials were of combination
therapies.
47 (66.2%) of the trials employing progression-free survival
(PFS) as a primary or coprimary outcome used randomized
comparative designs.
18 (5.7%) of the single-arm trials used PFS as a primary or
co-primary outcome.
The median number of patients analyzed in the random-
ized comparative trials was 131 compared with 43 for the
single-arm trials.
29 (28.2%) of the randomized comparative trials came to a
positive conclusion compared with 152 (72.7%) of the sin-
gle-arm trials.
More than 50% of the trials of cytotoxic, combination, and
targeted therapies used either tumor response, PFS, or a di-
chotomized version of PFS as a primary or coprimary
outcome.
35 (34%) of the trials of targeted therapies used tumor re-
sponse as a primary or coprimary outcome, whereas
16 (15.5%) used PFS.
R
EV
IEW
6 | JNCI J Natl Cancer Inst, 2019, Vol. 111, No. 12
D
ow
nloaded from
 https://academ
ic.oup.com
/jnci/advance-article-abstract/doi/10.1093/jnci/djz126/5520955 by U
niversity of N
ew
castle user on 29 O
ctober 2019
This debate is further complicated by the emergence of sev-
eral drugs with extremely high response rates in novel
biomarker-guided patient subgroups. Given these remarkable re-
sponse rates, it has been argued that randomized trials may be
unnecessary and unjustifiable on ethical grounds (69,90).
However, it has been noted that this remains an extremely un-
usual situation (33,89,91). Thus, only in rare cases would it be
unethical to randomize, and we should not let such findings
guide our overall development strategy (33,88), with several
authors even advocating for randomized designs to be used more
often in phase I (88,92). Nevertheless, Selaru et al. describe a vari-
ety of settings in which dramatic activity would be enough to li-
cense a monotherapy MTA on the basis of a single-arm trial (93).
So too have Simon et al. described the potential future role of tu-
mor response as a basis for licensing (72). They emphasize,
though, that the utilization of classical phase II designs remains
reliant on the choice of historical controls. Thus, guidelines from
regulatory bodies on how to achieve appropriate use of historical
comparator groups will be paramount to future trials.
Discussion
Many years have now passed since the beginnings of the debate
on optimal phase II oncology trial design and yet it remains
a subject of ongoing deliberation (see, eg, Grossman et al. [94]
for a recent examination in the context of glioblastoma).
Furthermore, although this debate has contributed to an in-
crease in the number of randomized phase II trials, phase II de-
sign for cytotoxic and targeted therapies remains similar, and
we remain without evidence that the use of randomized designs
in phase II has improved outcomes in phase III.
Little has changed in terms of the importance of resolving
this debate. Accordingly, all new guidance on phase II oncology
trial design remains extremely valuable. Such guidance will be
key to the effectual design of future studies.
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